Advanced search
Publication Cover
Annals of Medicine Volume 34, 2002 - Issue 7
Submit an article Journal homepage
832
Views
171
CrossRef citations to date
0
Altmetric
Research Article

Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer

Nayahmka J McGriff Departments of Pharmacy and Laboratory Medicine, Warren G. Magnuson Clinical Center; and the Clinical Endocrinology Branch and Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.
,
Gyorgy Csako Departments of Pharmacy and Laboratory Medicine, Warren G. Magnuson Clinical Center; and the Clinical Endocrinology Branch and Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.
,
Loukas Gourgiotis Departments of Pharmacy and Laboratory Medicine, Warren G. Magnuson Clinical Center; and the Clinical Endocrinology Branch and Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.
,
Lori C Guthrie Departments of Pharmacy and Laboratory Medicine, Warren G. Magnuson Clinical Center; and the Clinical Endocrinology Branch and Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.
,
Frank Pucino Departments of Pharmacy and Laboratory Medicine, Warren G. Magnuson Clinical Center; and the Clinical Endocrinology Branch and Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.
&
Nicholas J Sarlis Departments of Pharmacy and Laboratory Medicine, Warren G. Magnuson Clinical Center; and the Clinical Endocrinology Branch and Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.
Pages 554-564 | Published online: 08 Jul 2009

Citations (171)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Xinyang Li, Lin Yan, Jing Xiao, Yingying Li, Yaqiong Zhu, Zhen Yang, Mingbo Zhang & Yukun Luo. (2023) Optimal thyrotropin level for low-risk papillary thyroid carcinoma after ultrasound-guided radiofrequency ablation. International Journal of Hyperthermia 40:1.
Read now
Victor Bernet & Robert Smallridge. (2014) New therapeutic options for advanced forms of thyroid cancer. Expert Opinion on Emerging Drugs 19:2, pages 225-241.
Read now
Olov Norlen, Anthony R Glover, Justin S Gundara, Julian CY Ip & Stan B Sidhu. (2014) Best practice for the management of pediatric thyroid cancer. Expert Review of Endocrinology & Metabolism 9:2, pages 175-182.
Read now
Jennifer A Sipos & Ernest L Mazzaferri. (2008) The therapeutic management of differentiated thyroid cancer. Expert Opinion on Pharmacotherapy 9:15, pages 2627-2637.
Read now

Articles from other publishers (167)

Ruo-Yun Zhou, Ning Li, Hai-Long Tan, Neng Tang, Pei Chen, Mian Liu, Deng-Jie Ou-Yang, Zi-En Qin, Lei Ai, Bo Wei, Ya-Xin Zhao, Shi Chang & Peng Huang. (2023) Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer. Frontiers in Endocrinology 14.
Crossref
Kiyomi Horiuchi, Mikiko Fujimoto, Kamio Hidenori, Yusaku Yoshida, Eiichiro Noguchi, Yoko Omi & Takahiro Okamoto. (2023) Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma. World Journal of Surgery.
Crossref
Arash Abiri, Theodore Nguyen, Khodayar Goshtasbi, Sina J. Torabi, Edward C. Kuan, William B. Armstrong, Tjoson Tjoa & Yarah M. Haidar. (2023) A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer. European Archives of Oto-Rhino-Laryngology 280:5, pages 2525-2533.
Crossref
Arash Abiri, Khodayar Goshtasbi, Sina J. Torabi, Edward C. Kuan, William B. Armstrong, Tjoson Tjoa & Yarah M. Haidar. (2022) Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer. Otolaryngology–Head and Neck Surgery 168:4, pages 745-753.
Crossref
Jan Drugda, Jan Čáp, Mikuláš Kosák & Filip Gabalec. (2023) Levothyroxine suppressive therapy in differentiated thyroid cancer treatment. Vnitřní lékařství 69:2, pages 128-131.
Crossref
Dilek Gogas Yavuz, Ceyda D. Yazan, Zeliha Hekimsoy, Kadriye Aydin, Naile Gokkaya, Canan Ersoy, Aysen Akalın, Omercan Topaloglu, Berna I. Aydogan, Esra N. A. Dilekci, Ziynet Alphan Uc, Guven B. Cansu, Levent Ozsari, Ozlem T. Iyidir, Mehtap E. Olgun, Lezzan Keskin, Meral Mert, Bulent Can, Kaan Gungor, Tayfun Galip, Zeynep Cantürk, Gulsah Elbuken, Zafer Pekkolay, Nilufer O. Kutbay, Goknur Yorulmaz, Ahmet T. Kalkan, Yasemin A. Unsal, Adnan Yay, Baris Karagun & Evin Bozkur. (2022) Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients. Clinical Endocrinology 97:6, pages 833-840.
Crossref
Pradipta Kumar Parida, Karthik Herkal, Chapity Preetam, Pradeep Pradhan, Dillip Kumar Samal & Saurav Sarkar. (2020) Analysis of Pattern of Laryngotracheal Invasion by Papillary Thyroid Carcinoma and Their Management: Our Experience. Indian Journal of Otolaryngology and Head & Neck Surgery 74:S2, pages 1920-1928.
Crossref
Shiwei Wang, Yu Wang, Li Zhu, Liang He, Mutian Lv, Hao Zhang, Haoyu Wang, Fan Zhang, Yaxin Lai, Yushu Li, Zhongyan Shan & Weiping Teng. (2022) Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study. Endocrine 79:1, pages 113-124.
Crossref
Hyunju Park, Jun Park, Heejin Yoo, Seonwoo Kim, Jang Hyun Koh, Jae Hwan Jee, Yong‐Ki Min, Jae Hoon Chung, Tae Hyuk Kim, Mira Kang & Sun Wook Kim. (2022) Bone‐density testing interval and transition to osteoporosis in differentiated thyroid carcinoma patients on TSH suppression therapy. Clinical Endocrinology 97:1, pages 130-136.
Crossref
Shinje Moon, Ka Hee Yi & Young Joo Park. (2022) Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis. Cancers 14:10, pages 2382.
Crossref
Wissal Abassi, Nejmeddine Ouerghi & Anissa Bouassida. 2022. Hypothyroidism - New Aspects of an Old Disease. Hypothyroidism - New Aspects of an Old Disease.
Ho-Ryun Won, Eonju Jeon, Jae Won Chang, Yea Eun Kang, Kunho Song, Sun Wook Kim, Dong Mee Lim, Tae Kwun Ha, Ki-Wook Chung, Hyo-Jeong Kim, Young Joo Park & Bon Seok Koo. (2022) Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis. Cancers 14:6, pages 1470.
Crossref
Jun Choul Lee, Byong-Sop Song, Young Mi Kang, Yu-Ri Kim, Yea Eun Kang, Ju Hee Lee, Minho Shong & Hyon-Seung Yi. (2021) Effect of Thyroid-Stimulating Hormone Suppression on Muscle Function After Total Thyroidectomy in Patients With Thyroid Cancer. Frontiers in Endocrinology 12.
Crossref
Fabian Nordell, Ghadir Hallal, Pernilla Asp & Martin Almquist. (2021) Optimization of follow-up in patients with papillary thyroid cancer who show no evidence of disease 9–12 months after treatment. BJS Open 5:6.
Crossref
Sema Hepsen, Davut Sakiz, Hilal Erken Pamukcu, Ismail Emre Arslan, Hakan Duger, Pinar Akhanli, Muhammed Erkam Sencar, Ilknur Ozturk Unsal, Bekir Ucan, Muhammed Kizilgul & Erman Cakal. (2021) The Assessment of Ventricular Arrhythmia Indicators Based on Electrocardiography in Patients With Differentiated Thyroid Cancer Followed Up With Levothyroxine Suppression. Angiology 72:7, pages 657-663.
Crossref
Mabel RyderMark WentworthAlicia Algeciras-SchimnichJohn C. MorrisJames GarrityJane SandersStuart YoungPaul SandersJadwiga FurmaniakBernard Rees Smith. (2021) Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy. Thyroid.
Crossref
Max A. Schumm, Melissa G. Lechner, Michelle L. Shu, Joana E. Ochoa, Jiyoon Kim, Chi-Hong Tseng, Angela M. Leung & Michael W. Yeh. (2021) Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer. Endocrine Practice 27:7, pages 691-697.
Crossref
Eun Kyung Lee, Yea Eun Kang, Young Joo Park, Bon Seok Koo, Ki-Wook Chung, Eu Jeong Ku, Ho-Ryun Won, Won Sang Yoo, Eonju Jeon, Se Hyun Paek, Yong Sang Lee, Dong Mee Lim, Yong Joon Suh, Ha Kyoung Park, Hyo-Jeong Kim, Bo Hyun Kim, Mijin Kim, Sun Wook Kim, Ka Hee Yi, Sue K. Park, Eun-Jae Jung, June Young Choi, Ja Seong Bae, Joon Hwa Hong, Kee-Hyun Nam, Young Ki Lee, Hyeong Won Yu, Sujeong Go & Young Mi Kang. (2021) A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol. Endocrinology and Metabolism 36:3, pages 574-581.
Crossref
Song Jae Lee, Chang Myeon Song, Yong Bae Ji, Yun Young Choi, Young Seok Sohn, Jung Hwan Park, Dong Sun Kim & Kyung Tae. (2021) Risk factors for hypothyroidism and thyroid hormone replacement after hemithyroidectomy in papillary thyroid carcinoma. Langenbeck's Archives of Surgery 406:4, pages 1223-1231.
Crossref
SY Kang, HR Ahn, HJ Youn & SH Jung. (2021) Prognosis of papillary thyroid carcinoma in relation to preoperative subclinical hypothyroidism. The Annals of The Royal College of Surgeons of England 103:5, pages 367-373.
Crossref
Carla COLOMBO, Noemi GIANCOLA & Laura FUGAZZOLA. (2021) Personalized treatment for differentiated thyroid cancer: current data and new perspectives. Minerva Endocrinology 46:1.
Crossref
Pelin Basım, Derya Argun & Yaşar Özdenkaya. (2020) Self‐reported medication adherence in differentiated thyroid cancer survivors: Role of illness perception and medication beliefs. Head & Neck 43:2, pages 428-437.
Crossref
Carla GAMBALE, Rossella ELISEI & Antonio MATRONE. (2021) Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review. Minerva Endocrinologica 45:4.
Crossref
Cosimo Durante & Sebastiano Filetti. 2021. Surgery of the Thyroid and Parathyroid Glands. Surgery of the Thyroid and Parathyroid Glands 204 212.e3 .
Tomasz Bednarczuk. 2021. 70 Years of Levothyroxine. 70 Years of Levothyroxine 109 120 .
Swaytha Yalamanchi & David S. Cooper. 2021. Thyroid Cancer. Thyroid Cancer 147 157 .
Federico Hawkins Carranza, Sonsoles Guadalix Iglesias, María Luisa De Mingo Domínguez, Cristina Martín‐Arriscado Arroba, Begoña López Álvarez, Gonzalo Allo Miguel & Guillermo Martínez Díaz‐Guerra. (2020) Trabecular bone deterioration in differentiated thyroid cancer: Impact of long‐term TSH suppressive therapy. Cancer Medicine 9:16, pages 5746-5755.
Crossref
Yu-De Chu & Chau-Ting Yeh. (2020) The Molecular Function and Clinical Role of Thyroid Stimulating Hormone Receptor in Cancer Cells. Cells 9:7, pages 1730.
Crossref
Yogesh More, Aly Bernard Khalil, Huda Mustafa, Manjiri Gupte, Musa Al-Abbadi, Doua Elamin, Luaay Aziz & Shaik Irfan Basha. (2020) Incidental Thyroid cancer in patients undergoing surgery for hyperthyroidism. American Journal of Otolaryngology 41:2, pages 102187.
Crossref
E. Gallardo, J. Medina, J. C. Sánchez, A. Viúdez, E. Grande, I. Porras, T. Ramón y Cajal, J. Trigo, L. Iglesias & J. Capdevila. (2020) SEOM clinical guideline thyroid cancer (2019). Clinical and Translational Oncology 22:2, pages 223-235.
Crossref
Marco Castellana, Carlo Castellana, Luca Giovanella & Pierpaolo Trimboli. (2020) Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?. Endocrine 67:2, pages 281-290.
Crossref
Mohammadmehdi Adhami, Peter Michail, Apoorva Rao, Chhavi R. Bhatt, Simon Grodski, Jonathan W. Serpell & James C. Lee. (2019) Anti-Thyroid Antibodies and TSH as Potential Markers of Thyroid Carcinoma and Aggressive Behavior in Patients with Indeterminate Fine-Needle Aspiration Cytology. World Journal of Surgery 44:2, pages 363-370.
Crossref
Yasuhiro Ito, Naoyoshi Onoda & Takahiro Okamoto. (2020) The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer. Endocrine Journal 67:7, pages 669-717.
Crossref
Chunhua Liu, Haihong Lv, Qian Li, Songbo Fu, Jiaojiao Tan, Chenyi Wang, Xiaoqian Wang & Yuping Ma. (2020) Effect of thyrotropin suppressive therapy on heart rate variability and QT dispersion in patients with differentiated thyroid cancer. Medicine 99:28, pages e21190.
Crossref
Ammar Asban, Anish J. Patel, Sushanth Reddy, Thomas Wang, Courtney J. Balentine & Herbert Chen. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1074 1107.e11 .
S. Filetti, C. Durante, D. Hartl, S. Leboulleux, L.D. Locati, K. Newbold, M.G. Papotti & A. Berruti. (2019) Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 30:12, pages 1856-1883.
Crossref
Giorgio Grani, Valeria Ramundo, Antonella Verrienti, Marialuisa Sponziello & Cosimo Durante. (2019) Thyroid hormone therapy in differentiated thyroid cancer. Endocrine 66:1, pages 43-50.
Crossref
Bernadette Biondi & David S. Cooper. (2019) Thyroid Hormone Suppression Therapy. Endocrinology and Metabolism Clinics of North America 48:1, pages 227-237.
Crossref
Joanna Klubo-Gwiezdzinska, Sungyoung Auh, Marvin Gershengorn, Brianna Daley, Athanasios Bikas, Kenneth Burman, Leonard Wartofsky, Mark Urken, Eliza Dewey, Robert Smallridge, Ana-Maria Chindris & Electron Kebebew. (2019) Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer. JAMA Network Open 2:2, pages e187754.
Crossref
Myung-Chul Lee, Min Joo Kim, Hoon Sung Choi, Sun Wook Cho, Guk Haeng Lee, Young Joo Park & Do Joon Park. (2019) Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer. Endocrinology and Metabolism 34:2, pages 150.
Crossref
Byung-Ho YoonYoujin LeeHyun Jin OhSung Han KimYoung-Kyun Lee. (2019) Influence of Thyroid-stimulating Hormone Suppression Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Cancer: A Meta-analysis. Journal of Bone Metabolism 26:1, pages 51.
Crossref
Youjin LeeByung-Ho YoonSeeyoun LeeYoun Kyung ChungYoung-Kyun Lee. (2019) Risk of Osteoporotic Fractures after Thyroid-stimulating Hormone Suppression Therapy in Patients with Thyroid Cancer. Journal of Bone Metabolism 26:1, pages 45.
Crossref
Eun Heui KimYun Kyung JeonKyoungjune PakIn-Joo KimSeong-Jang KimSeunghyeon ShinBo Hyun KimSang Soo KimByung-Joo LeeJeong-Gyu LeeTae Sik GohKeunyoung Kim. (2019) Effects of Thyrotropin Suppression on Bone Health in Menopausal Women with Total Thyroidectomy. Journal of Bone Metabolism 26:1, pages 31.
Crossref
Rami Alrezk & Joanna Klubo-Gwiezdzinska. 2019. The Thyroid and Its Diseases. The Thyroid and Its Diseases 711 720 .
L. Conte, E. Monti, S. Gay, P. Marroni, A. Adorno, M. Mittica, M. Mussap & M. Giusti. (2018) Evaluation of adequacy of levo-thyroxine dosage in patients with differentiated thyroid carcinoma: correlation between morning and afternoon TSH determination. Journal of Endocrinological Investigation 41:10, pages 1193-1197.
Crossref
Hani O. Nasef, Iain J. Nixon & Volkert B. Wreesmann. (2018) Optimization of the risk-benefit ratio of differentiated thyroid cancer treatment. European Journal of Surgical Oncology 44:3, pages 276-285.
Crossref
Kyunghee KimMee Ock GuJung Hwa JungJong Ryeal HahmSoo Kyoung KimJin Hyun KimSeung Hoon Woo. (2018) Efficacy of a Home-Based Exercise Program After Thyroidectomy for Thyroid Cancer Patients. Thyroid 28:2, pages 236-245.
Crossref
Andrea R. Marcadis, Jennifer Cracchiolo & Ashok K. Shaha. 2018. Evidence-Based Endocrine Surgery. Evidence-Based Endocrine Surgery 85 95 .
David A. Pattison, Julie A. Miller, Bhadrakant Khavar & Jeanne Tie. 2018. Evidence-Based Endocrine Surgery. Evidence-Based Endocrine Surgery 121 140 .
Hiro Ishii, Dae S. Kim & John C. Watkinson. 2018. Practical Management of Thyroid Cancer. Practical Management of Thyroid Cancer 77 97 .
Jonathan Mark Fussey, Habib Khan, Farhan Ahsan, Ravi Prashant & Laura Pettit. (2017) Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach. Head & Neck 39:12, pages 2567-2572.
Crossref
Sumito Jitsukawa, Ryuta Kamekura, Koji Kawata, Fumie Ito, Akinori Sato, Hiroshi Matsumiya, Tomonori Nagaya, Keiji Yamashita, Terufumi Kubo, Tomoki Kikuchi, Noriyuki Sato, Tadashi Hasegawa, Hiroshi Kiyonari, Yoshiko Mukumoto, Ken-ichi Takano, Tetsuo Himi & Shingo Ichimiya. (2017) Loss of sorting nexin 5 stabilizes internalized growth factor receptors to promote thyroid cancer progression. The Journal of Pathology 243:3, pages 342-353.
Crossref
Hye In Kim, Tae Hyuk Kim, Hosu Kim, Young Nam Kim, Hye Won Jang, Jung-Han Kim, Kyu Yeon Hur, Jae Hoon Chung & Sun Wook Kim. (2017) Delayed TSH recovery after dose adjustment during TSH-suppressive levothyroxine therapy of thyroid cancer. Clinical Endocrinology 87:3, pages 286-291.
Crossref
Yuya Sasaki, Masao Seto, Hiroaki Miyoshi, Shinya Okada, Shintaro Yokoyama, Akira Ohshima & Koichi Ohshima. (2017) Papillary thyroid carcinoma expressing CD20. Pathology International 67:7, pages 350-354.
Crossref
Jeonghoon Ha & Dong Jun Lim. (2017) Guidelines for the Postoperative Treatment of Thyroid Cancer: Levothyroxine and Calcium/Vitamin D Supplements. The Korean Journal of Medicine 92:3, pages 245-250.
Crossref
Christopher W Rowe, Jonathan W Paul, Craig Gedye, Jorge M Tolosa, Cino Bendinelli, Shaun McGrath & Roger Smith. (2017) Targeting the TSH receptor in thyroid cancer. Endocrine-Related Cancer 24:6, pages R191-R202.
Crossref
B. Freudenthal & G.R. Williams. (2017) Thyroid Stimulating Hormone Suppression in the Long-term Follow-up of Differentiated Thyroid Cancer. Clinical Oncology 29:5, pages 325-328.
Crossref
J. Capdevila, J. C. Galofré, E. Grande, C. Zafón Llopis, T. Ramón y Cajal Asensio, E. Navarro González, P. Jiménez-Fonseca, J. Santamaría Sandi, J. M. Gómez Sáez & G. Riesco Eizaguirre. (2016) Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI). Clinical and Translational Oncology 19:3, pages 279-287.
Crossref
Yash R. Somnay, Xiao-Min Yu, Ricardo V. Lloyd, Glen Leverson, Zviadi Aburjania, Samuel Jang, Renata Jaskula-Sztul & Herbert Chen. (2017) Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis. Cancer 123:5, pages 769-782.
Crossref
景菊 莫. (2017) Research Progress of Differentiated Thyroid Carcinoma. Medical Diagnosis 07:03, pages 60-64.
Crossref
Naifa Lamki Busaidy & Tania Jaber. 2017. Management of Differentiated Thyroid Cancer. Management of Differentiated Thyroid Cancer 263 280 .
Hannah Nieto & Kristien Boelaert. (2016) WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?. Endocrine-Related Cancer 23:11, pages T109-T121.
Crossref
Garcilaso Riesco-Eizaguirre, Juan Carlos Galofré, Enrique Grande, Carles Zafón Llopis, Teresa Ramón y Cajal Asensio, Elena Navarro González, Paula Jiménez-Fonseca, Javier Santamaría Sandi, José Manuel Gómez Sáez & Jaume Capdevila. (2016) Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer. Endocrinología y Nutrición 63:4, pages e17-e24.
Crossref
Garcilaso Riesco-Eizaguirre, Juan Carlos Galofré, Enrique Grande, Carles Zafón Llopis, Teresa Ramón y Cajal Asensio, Elena Navarro González, Paula Jiménez-Fonseca, Javier Santamaría Sandi, José Manuel Gómez Sáez & Jaume Capdevila. (2016) Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer. Endocrinología y Nutrición (English Edition) 63:4, pages e17-e24.
Crossref
Kyoung Sik Park. (2016) TSH Suppression after Differentiated Thyroid Cancer Surgery and Osteoporosis. Korean Journal of Endocrine Surgery 16:1, pages 1.
Crossref
Yong Sang Lee, Hang-Seok Chang & Cheong Soo Park. (2016) Changing trends in the management of well-differentiated thyroid carcinoma in Korea. Endocrine Journal 63:6, pages 515-521.
Crossref
Kyung-Soon Hong, Jung-Woo Son, Ohk Hyun Ryu, Moon-Gi Choi, Ji Yeon Hong & Seong Jin Lee. (2016) Cardiac Effects of Thyrotropin Oversuppression with Levothyroxine in Young Women with Differentiated Thyroid Cancer. International Journal of Endocrinology 2016, pages 1-6.
Crossref
Ka Hee YiEun Kyung LeeHo-Cheol KangYunwoo KohSun Wook KimIn Joo KimDong Gyu NaKee-Hyun NamSo Yeon ParkJin Woo ParkSang Kyun BaeSeung-Kuk BaekJung Hwan BaekByung-Joo LeeKi-Wook ChungYuh-Seog JungGi Jeong CheonWon Bae KimJae Hoon ChungYoung-Soo Rho. (2016) 2016 Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. International Journal of Thyroidology 9:2, pages 59.
Crossref
Bryan R. HaugenErik K. AlexanderKeith C. BibleGerard M. DohertySusan J. MandelYuri E. NikiforovFurio PaciniGregory W. RandolphAnna M. SawkaMartin SchlumbergerKathryn G. SchuffSteven I. ShermanJulie Ann SosaDavid L. StewardR. Michael TuttleLeonard Wartofsky. (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1, pages 1-133.
Crossref
Jenny Y. Yoo & Michael T. Stang. (2016) Current Guidelines for Postoperative Treatment and Follow-Up of Well-Differentiated Thyroid Cancer. Surgical Oncology Clinics of North America 25:1, pages 41-59.
Crossref
Nasheed M. Hossain, Colleen Veloski & Ranee Mehra. 2016. Head and Neck Cancer. Head and Neck Cancer 673 692 .
Swaytha Yalamanchi & David Cooper. 2016. Thyroid Cancer. Thyroid Cancer 159 166 .
Victor J. Bernet. 2016. Thyroid Cancer. Thyroid Cancer 371 376 .
Henning Dralle, Andreas Machens, Johanna Basa, Vahab Fatourechi, Silvia Franceschi, Ian D. Hay, Yuri E. Nikiforov, Furio Pacini, Janice L. Pasieka & Steven I. Sherman. (2015) Follicular cell-derived thyroid cancer. Nature Reviews Disease Primers 1:1.
Crossref
Laura Moss. 2015. Practical Clinical Oncology. Practical Clinical Oncology 513 527 .
Aubrey A. Carhill, Danielle R. Litofsky, Douglas S. Ross, Jacqueline Jonklaas, David S. Cooper, James D. Brierley, Paul W. Ladenson, Kenneth B. Ain, Henry G. Fein, Bryan R. Haugen, James Magner, Monica C. Skarulis, David L. Steward, Mingxhao Xing, Harry R. Maxon & Steven I. Sherman. (2015) Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987–2012. The Journal of Clinical Endocrinology & Metabolism 100:9, pages 3270-3279.
Crossref
A. Pfestroff, M. Dietlein & M. Luster. (2015) Nuklearmedizinische Diagnostik, Therapie und Nachsorge des SchilddrüsenkarzinomsNuclear medicine diagnostic procedures, treatment, and follow-up of thyroid carcinoma. Der Onkologe 21:7, pages 597-610.
Crossref
Niveen A. Abo-Touk & Dalia H. Zayed. (2015) The Efficacy of Thyrotropin Suppression Therapy in Treatment of Differentiated Thyroid Cancer after Total Thyroidectomy. Forum of Clinical Oncology 6:2, pages 24-33.
Crossref
C. Do Cao & J.-L. Wémeau. (2015) Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer. Annales d'Endocrinologie 76:1, pages 1S47-1S52.
Crossref
Tom Edward Ngo LoAbigail Uy CantoPatricia Deanna D. Maningat. (2015) Risk Factors for Recurrence in Filipinos with Well-Differentiated Thyroid Cancer. Endocrinology and Metabolism 30:4, pages 543.
Crossref
Linwah Yip. 2015. Surgical Endocrinopathies. Surgical Endocrinopathies 83 97 .
Jocelyn F. Burke & Herbert Chen. 2015. Surgical Oncology. Surgical Oncology 539 561 .
Jiang-rong Luo, Chun-bao Xie & Zhi-hui Li. (2014) Treatment for Malignant Struma Ovarii in the Eyes of Thyroid Surgeons. Medicine 93:26, pages e147.
Crossref
Petros Perros, Kristien Boelaert, Steve Colley, Carol Evans, Rhodri M Evans, Georgina Gerrard BA, Jackie Gilbert, Barney Harrison, Sarah J Johnson, Thomas E Giles, Laura Moss, Val Lewington, Kate Newbold, Judith Taylor, Rajesh V Thakker, John Watkinson & Graham R. Williams. (2014) Guidelines for the management of thyroid cancer. Clinical Endocrinology 81, pages 1-122.
Crossref
Masato Kobayashi, Hiroshi Wakabayashi, Daiki Kayano, Takahiro Konishi, Hironori Kojima, Hiroto Yoneyama, Koichi Okuda, Hiroyuki Tsushima, Masahisa Onoguchi, Keiichi Kawai & Seigo Kinuya. (2014) Application of a medium-energy collimator for I-131 imaging after ablation treatment of differentiated thyroid cancer. Annals of Nuclear Medicine 28:6, pages 551-558.
Crossref
Bernadette BiondiLeonard Wartofsky. (2014) Treatment With Thyroid Hormone. Endocrine Reviews 35:3, pages 433-512.
Crossref
Iwao Sugitani, Yoshihide Fujimoto & Keiko Yamada. (2013) Association Between Serum Thyrotropin Concentration and Growth of Asymptomatic Papillary Thyroid Microcarcinoma. World Journal of Surgery 38:3, pages 673-678.
Crossref
D. Ahn, J. H. Sohn, J. H. Jeon & J. Y. Jeong. (2014) Clinical impact of microscopic extrathyroidal extension in patients with papillary thyroid microcarcinoma treated with hemithyroidectomy. Journal of Endocrinological Investigation 37:2, pages 167-173.
Crossref
Tobias CarlingRobert Udelsman. (2014) Thyroid Cancer. Annual Review of Medicine 65:1, pages 125-137.
Crossref
Yuki MORI, Takashi KOSHIKAWA, Junko OZEKI, Noriko SHIBATA, Nanae UEDA, Ei-ichi SASAKI, Yoshiko MURAKAMI, Waki HOSODA, Yasushi YATABE & Yasuhisa HASEGAWA. (2014) Significance of serum thyrotropin concentration in patients with negative diagnosis of thyroid fine-needle aspiration cytology. The Journal of the Japanese Society of Clinical Cytology 53:5, pages 356-361.
Crossref
Makoto Kammori, Tatsuya Fukumori, Yoshiyuki Sugishita, Masae Hoshi & Tetsu Yamada. (2014) Therapeutic strategy for low-risk thyroid cancer in Kanaji Thyroid Hospital [Review]. Endocrine Journal 61:1, pages 1-12.
Crossref
David F. Schneider, Haggi Mazeh, Sam J. Lubner, Juan C. Jaume & Herbert Chen. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1112 1142.e7 .
David F. Schneider & Herbert Chen. (2013) New developments in the diagnosis and treatment of thyroid cancer. CA: A Cancer Journal for Clinicians 63:6, pages 373-394.
Crossref
Cosimo Durante, Giuseppe Costante & Sebastiano Filetti. (2013) Differentiated thyroid carcinoma: defining new paradigms for postoperative management. Endocrine-Related Cancer 20:4, pages R141-R154.
Crossref
Donald SA McLeod, Anna M Sawka & David S Cooper. (2013) Controversies in primary treatment of low-risk papillary thyroid cancer. The Lancet 381:9871, pages 1046-1057.
Crossref
Minoru Fujimori, Hisato Hara & Hidemitsu Tsutsui. 2013. Treatment of Thyroid Tumor. Treatment of Thyroid Tumor 289 290 .
Kaoru Kobayashi, Akira Yoshida & Takehito Igarashi. 2013. Treatment of Thyroid Tumor. Treatment of Thyroid Tumor 149 151 .
Leigh Delbridge. 2013. Patient Surveillance After Cancer Treatment. Patient Surveillance After Cancer Treatment 63 68 .
Concetto RegalbutoFrancesco Frasca, Gabriella Pellegriti, Pasqualino Malandrino, Ilenia Marturano, Isidoro Di Carlo & Vincenzo Pezzino. (2012) Update on thyroid cancer treatment. Future Oncology 8:10, pages 1331-1348.
Crossref
M. Campos, I. van Hoek, K. Peremans & S. Daminet. (2012) Recombinant Human Thyrotropin in Veterinary Medicine: Current Use and Future Perspectives. Journal of Veterinary Internal Medicine 26:4, pages 853-862.
Crossref
Katsuhiro Tanaka & Hiroshi Sonoo. (2011) Current trends in TSH suppression therapy for patients with papillary thyroid carcinoma in Japan: results of a questionnaire distributed to councilors of the Japanese Society of Thyroid Surgery. Surgery Today 42:7, pages 633-638.
Crossref
Kara Meinke Baehr, Elizabeth Lyden, Kelly Treude, Judi Erickson & Whitney Goldner. (2012) Levothyroxine dose following thyroidectomy is affected by more than just body weight. The Laryngoscope 122:4, pages 834-838.
Crossref
Carles Zafón. (2012) Tratamiento supresor de la TSH en el cáncer diferenciado de tiroides. Un dogma en revisión. Endocrinología y Nutrición 59:2, pages 125-130.
Crossref
Carles Zafón. (2012) TSH-suppressive treatment in differentiated thyroid cancer. A dogma under review. Endocrinología y Nutrición (English Edition) 59:2, pages 125-130.
Crossref
Deepak Khandelwal & Nikhil Tandon. (2012) Overt and Subclinical Hypothyroidism. Drugs 72:1, pages 17-33.
Crossref
Barbara Jarząb & Daria Handkiewicz-Junak. 2012. Clinical Approach to Well-differentiated Thyroid Cancers. Clinical Approach to Well-differentiated Thyroid Cancers 125 143 .
Geneviève Rondeau & Robert Michael Tuttle. 2012. Surgery of the Thyroid and Parathyroid Glands. Surgery of the Thyroid and Parathyroid Glands 339 351 .
Martin A. Walter, Rebecca A. Dumont, Jan Mueller-Brand & Frank Zimmermann. 2012. Surgery of the Thyroid and Parathyroid Glands. Surgery of the Thyroid and Parathyroid Glands 313 326 .
Otmar Schober & Burkhard Riemann. 2014. Therapeutic Nuclear Medicine. Therapeutic Nuclear Medicine 275 281 .
Iwao Sugitani & Yoshihide Fujimoto. (2011) Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: A prospective controlled study. Surgery 150:6, pages 1250-1257.
Crossref
Hiroshi Wakabayashi, Kenichi Nakajima, Makoto Fukuoka, Anri Inaki, Ayane Nakamura, Daiki Kayano & Seigo Kinuya. (2011) Double-phase 131I whole body scan and 131I SPECT-CT images in patients with differentiated thyroid cancer: their effectiveness for accurate identification. Annals of Nuclear Medicine 25:9, pages 609-615.
Crossref
Javier Martínez Trufero, Jaume Capdevilla, Juan Jesús Cruz & Dolores Isla. (2011) SEOM clinical guidelines for the treatment of thyroid cancer. Clinical and Translational Oncology 13:8, pages 574-579.
Crossref
Hendrieke C Hoftijzer, Ellen Kapiteijn, Tatiana Schneider, Guido C Hovens, Hans Morreau, Hans Gelderblom & Johannes WA Smit. (2011) Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. Clinical Investigation 1:2, pages 241-253.
Crossref
Ka Hee YiYoung Joo ParkSung-Soo KoongJung-Han KimDong Gyu NaJin-Sook RyuSo Yeon ParkIn Ae ParkChung-Hwan BaekYoung Kee ShongYoung Don LeeJaetae LeeJeong Hyun LeeJae Hoon ChungChan Kwon JungSeung-Ho ChoiBo Youn Cho. (2011) Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. Journal of the Korean Society of Radiology 64:4, pages 389.
Crossref
Ka Hee YiYoung Joo ParkSung-Soo KoongJung-Han KimDong Gyu NaJin-Sook RyuSo Yeon ParkIn Ae ParkChung-Hwan BaekYoung Kee ShongYoung Don LeeJaetae LeeJeong Hyun LeeJae Hoon ChungChan Kwon JungSeung-Ho ChoiBo Youn Cho. (2011) Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. Korean Journal of Otorhinolaryngology-Head and Neck Surgery 54:1, pages 8.
Crossref
Hiroshi Takami, Yasuhiro Ito, Takahiro Okamoto & Akira Yoshida. (2010) Therapeutic Strategy for Differentiated Thyroid Carcinoma in Japan Based on a Newly Established Guideline Managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World Journal of Surgery 35:1, pages 111-121.
Crossref
Ranee Mehra, Charu Aggarwal & Roger B. Cohen. 2011. Head and Neck Cancer. Head and Neck Cancer 555 568 .
José Manuel Gómez Sáez. (2010) ¿Está de acuerdo nuestra conducta ante el nódulo tiroideo y cáncer diferenciado de tiroides con la guía norteamericana y el consenso europeo?. Endocrinología y Nutrición 57:8, pages 357-363.
Crossref
Victor Bernet. (2010) Approach to the Patient with Incidental Papillary Microcarcinoma. The Journal of Clinical Endocrinology & Metabolism 95:8, pages 3586-3592.
Crossref
J.A. Sipos & E.L. Mazzaferri. (2010) Thyroid Cancer Epidemiology and Prognostic Variables. Clinical Oncology 22:6, pages 395-404.
Crossref
N. Sharma, K. Boelaert & J.C. Watkinson. (2010) Who Should Treat Thyroid Cancer? A UK Surgical Perspective. Clinical Oncology 22:6, pages 413-418.
Crossref
H. Tala & R.M. Tuttle. (2010) Contemporary Post Surgical Management of Differentiated Thyroid Carcinoma. Clinical Oncology 22:6, pages 419-429.
Crossref
Hiroshi Uchida, Ken Yamazaki, Mariko Fukuma, Taketo Yamada, Tetsu Hayashida, Hirotoshi Hasegawa, Masaki Kitajima, Yuko Kitagawa & Michiie Sakamoto. (2010) Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Science 101:7, pages 1731-1737.
Crossref
George H. Sakorafas, Dimitrios Sampanis & Michael Safioleas. (2010) Cervical lymph node dissection in papillary thyroid cancer: Current trends, persisting controversies, and unclarified uncertainties. Surgical Oncology 19:2, pages e57-e70.
Crossref
Mingzhao Xing. (2010) Prognostic utility of BRAF mutation in papillary thyroid cancer. Molecular and Cellular Endocrinology 321:1, pages 86-93.
Crossref
Amin Sabet & Matthew Kim. (2010) Postoperative Management of Differentiated Thyroid Cancer. Otolaryngologic Clinics of North America 43:2, pages 329-351.
Crossref
Iwao Sugitani & Yoshihide Fujimoto. (2010) Management of low-risk papillary thyroid carcinoma: Unique conventional policy in Japan and our efforts to improve the level of evidence. Surgery Today 40:3, pages 199-215.
Crossref
Bernadette BiondiDavid S. Cooper. (2010) Benefits of Thyrotropin Suppression Versus the Risks of Adverse Effects in Differentiated Thyroid Cancer. Thyroid 20:2, pages 135-146.
Crossref
Ka Hee YiYoung Joo ParkSung-Soo KoongJung-Han KimDong Gyu NaJin-Sook RyuSo Yeon ParkIn Ae ParkChung-Hwan BaekYoung Kee ShongYoung Don LeeJaetae LeeJeong Hyun LeeJae Hoon ChungChan Kwon JungSeung-Ho ChoiBo Youn Cho. (2010) Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. Endocrinology and Metabolism 25:4, pages 270.
Crossref
Yasuhiro Ito, Hiroo Masuoka, Mitsuhiro Fukushima, Hiroyuki Inoue, Minoru Kihara, Chisato Tomoda, Takuya Higashiyama, Yuuki Takamura, Kaoru Kobayashi, Akihiro Miya & Akira Miyauchi. (2010) Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan. Endocrine Journal 57:6, pages 523-531.
Crossref
Stephen Y. Lai, Susan J. Mandel & Randal S. Weber. 2010. Cummings Otolaryngology - Head and Neck Surgery. Cummings Otolaryngology - Head and Neck Surgery 1750 1772 .
Carole Spencer & Ivana Petrovic. 2010. Thyroid Function Testing. Thyroid Function Testing 125 153 .
Linwah Yip & Sally E. Carty. 2010. Endocrine Neoplasia. Endocrine Neoplasia 35 56 .
David S. CooperGerard M. DohertyBryan R. HaugenRichard T. KloosStephanie L. LeeSusan J. MandelErnest L. MazzaferriBryan McIverFurio PaciniMartin SchlumbergerSteven I. ShermanDavid L. StewardR. Michael Tuttle. (2009) Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 19:11, pages 1167-1214.
Crossref
Pedro Weslley Rosario, Daniela Santos Salles & Saulo Purisch. (2009) Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth. Arquivos Brasileiros de Endocrinologia & Metabologia 53:6, pages 767-770.
Crossref
Anita K. Ying, Winston Huh, Sarah Bottomley, Douglas B. Evans & Steven G. Waguespack. (2009) Thyroid Cancer in Young Adults. Seminars in Oncology 36:3, pages 258-274.
Crossref
Jennifer Sipos & Ernest Mazzaferri. 2009. Medical Management of Thyroid Disease, Second Edition. Medical Management of Thyroid Disease, Second Edition 237 295 .
Naifa L. Busaidy & Richard T. Kloos. 2009. Clinical Management of Thyroid Disease. Clinical Management of Thyroid Disease 361 381 .
R. Michael Tuttle & Rebecca Leboeuf. 2009. Endocrine Surgery. Endocrine Surgery 137 148 .
Daniel L. Price, Richard J. Wong & Gregory W. Randolph. (2008) Invasive Thyroid Cancer: Management of the Trachea and Esophagus. Otolaryngologic Clinics of North America 41:6, pages 1155-1168.
Crossref
Jacqueline JonklaasHala Nsouli-MaktabiSteven J. Soldin. (2008) Endogenous Thyrotropin and Triiodothyronine Concentrations in Individuals with Thyroid Cancer. Thyroid 18:9, pages 943-952.
Crossref
G. Brabant. (2008) Thyrotropin Suppressive Therapy in Thyroid Carcinoma: What Are the Targets?. The Journal of Clinical Endocrinology & Metabolism 93:4, pages 1167-1169.
Crossref
Elizabeth G. Grubbs, Thereasa A. Rich, Guojun Li, Erich M. Sturgis, Maher N. Younes, Jeffrey N. Myers, Beth Edeiken-Monroe, Bruno D. Fornage, Douglas P. Monroe, Gregg A. Staerkel, Michelle D. Williams, Steven G. Waguespack, Mimi I. Hu, Gilbert Cote, Robert F. Gagel, James Cohen, Randal S. Weber, Daniel A. Anaya, F. Chris Holsinger, Nancy D. Perrier, Gary L. Clayman & Douglas B. Evans. (2008) Recent Advances in Thyroid Cancer. Current Problems in Surgery 45:3, pages 156-250.
Crossref
Sang Youl RheeYoung Seol Kim. (2008) Evidence Based Medicine in Endocrinology. Journal of Korean Endocrine Society 23:6, pages 379.
Crossref
Yong Sang LEE, Kee-Hyun NAM, Woong Youn CHUNG, Hang Seok CHANG, Naoyuki SHIGEMATSU, Hiroshi TAKAMI, Atsushi KUBO & Cheong Soo PARK. (2008) Practical Management of Well Differentiated Thyroid Carcinoma in Korea. Endocrine Journal 55:6, pages 1015-1024.
Crossref
Nicole Ehrhardt & Victor Bernet. 2008. A Case-Based Guide to Clinical Endocrinology. A Case-Based Guide to Clinical Endocrinology 109 119 .
. (2007) Recommandations. Annales d'Endocrinologie 68, pages 57-72.
Crossref
R. Michael Tuttle, Rébecca Leboeuf & Andrew J. Martorella. (2007) Papillary Thyroid Cancer: Monitoring and Therapy. Endocrinology and Metabolism Clinics of North America 36:3, pages 753-778.
Crossref
Furio Pacini, Martin Schlumberger, Henning Dralle, Rossella Elisei, Johannes W.A. Smit & Filmar Wiersinga. (2007) Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. Endocrinología y Nutrición 54:7, pages 390.e1-390.e16.
Crossref
Ana Luiza Maia, Laura S. Ward, Gisah A. Carvalho, Hans Graf, Rui M.B. Maciel, Léa M. Zanini Maciel, Pedro W. Rosário & Mario Vaisman. (2007) Nódulos de tireóide e câncer diferenciado de tireóide: consenso brasileiro. Arquivos Brasileiros de Endocrinologia & Metabologia 51:5, pages 867-893.
Crossref
Y. Nancy You & Samuel A. WellsJrJr. (2007) Role of Surgeons in Clinical Trials for Thyroid Cancer. World Journal of Surgery 31:5, pages 987-995.
Crossref
Matt Freeby & Robert J. McConnell. (2007) Differentiated thyroid cancer. Community Oncology 4:4, pages 197-204.
Crossref
Won Bae KimTae Yong KimHyuk Sang KwonWon-Jin MoonJae Bok LeeYoung Sik ChoiSeok Ki KimSun Wook KimKi-wook ChungJung Hwan BaekByung Il KimDo Joon ParkDong Gyu NaJun Ho ChoeJae Hoon ChungHye Seung JungJeong Han KimKee Hyun NamHang-Seok ChangWoong Youn ChungSoon Won HongSuck Joon HongJeong Hyun LeeKa Hee YiYoung Suk JoHo-Cheol KangMinho ShongJin Woo ParkJong Ho YoonSeong Joon KangKwang Woo Lee. (2007) Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. Journal of Korean Endocrine Society 22:3, pages 157.
Crossref
F. Duron. (2007) Hormonothérapie thyroïdienne freinatrice. Principes et modalités pratiques. EMC - Endocrinologie - Nutrition 4:3, pages 1-7.
Crossref
Jacqueline JonklaasNicholas J. SarlisDanielle LitofskyKenneth B. AinS. Thomas BigosJames D. BrierleyDavid S. CooperBryan R. HaugenPaul W. LadensonJames MagnerJacob RobbinsDouglas S. RossMonica SkarulisHarry R. MaxonSteven I. Sherman. (2006) Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy. Thyroid 16:12, pages 1229-1242.
Crossref
Julie Ann Sosa & Robert Udelsman. (2006) Papillary Thyroid Cancer. Surgical Oncology Clinics of North America 15:3, pages 585-601.
Crossref
David S. CooperGerard M. DohertyBryan R. HaugenRichard T. KloosStephanie L. LeeSusan J. MandelErnest L. MazzaferriBryan McIverSteven I. ShermanR. Michael Tuttle. (2006) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce. Thyroid 16:2, pages 109-142.
Crossref
David S. Cooper, Gerard M. Doherty, Bryan R. Haugen, Richard T. Kloos, Stephanie L. Lee, Susan J. Mandel, Ernest L. Mazzaferri, Bryan McIver, Steven I. Sherman & R. Michael Tuttle. (2006) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 0:0, pages 060118075408001.
Crossref
Naoyuki SHIGEMATSU, Hiroshi TAKAMI & Atsushi KUBO. (2006) Unique Treatment Policy for Well-differentiated Thyroid Cancer in Japan: Results of a Questionnaire Distributed to Members of the Japanese Society of Thyroid Surgery and the International Association of Endocrine Surgeons. Endocrine Journal 53:6, pages 829-839.
Crossref
Leonard Wartofsky. 2006. Thyroid Cancer. Thyroid Cancer 293 296 .
Nicholas J. Sarlis & Wellington Hung. 2006. Practical Management of Thyroid Cancer. Practical Management of Thyroid Cancer 303 320 .
Richard T. Kloos. (2005) Papillary thyroid cancer: Medical management and follow-up. Current Treatment Options in Oncology 6:4, pages 323-338.
Crossref
William L. Green. (2005) New questions regarding bioequivalence of levothyroxine preparations: A Clinician's response. The AAPS Journal 7:1, pages E54-E58.
Crossref
Naoyuki SHIGEMATSU, Hiroshi TAKAMI, Nobutake ITO & Atsushi KUBO. (2005) Nationwide Survey on the Treatment Policy for Well-differentiated Thyroid Cancer - Results of a Questionnaire Distributed at the 37th Meeting of The Japanese Society of Thyroid Surgery -. Endocrine Journal 52:4, pages 479-491.
Crossref
Nicholas J. Sarlis & Salvatore Benvenga. 2005. Molecular Basis of Thyroid Cancer. Molecular Basis of Thyroid Cancer 237 264 .
Ernest L. Mazzaferri. 2005. Essentials of Thyroid Cancer Management. Essentials of Thyroid Cancer Management 263 266 .
N. R. CaronO. H. Clark. (2016) Well Differentiated Thyroid Cancer. Scandinavian Journal of Surgery 93:4, pages 261-271.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.